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5-AzacytidineThe progressive restriction of differentiation potential from pluripotent embryonic stem cells, via
multipotent progenitor cells to terminally differentiated, mature somatic cells, involves step-wise changes
in transcription patterns that are tightly controlled by the coordinated action of key transcription factors
and changes in epigenetic modiﬁcations. While previous studies have demonstrated tissue-speciﬁc
differences in DNA methylation patterns that might function in lineage restriction, it is unclear at what
exact developmental stage these differences arise. Here, we have studied whether terminal, multi-lineage
differentiation of C2C12 myoblasts is accompanied by lineage-speciﬁc changes in DNA methylation
patterns. Using bisulﬁte sequencing and genome-wide methylated DNA- and chromatin immunoprecip-
itation-on-chip techniques we show that in these cells, in general, myogenic genes are enriched for RNA
polymerase II and hypomethylated, whereas osteogenic genes show lower polymerase occupancy and are
hypermethylated. Removal of DNA methylation marks by 5-azacytidine (5AC) treatment alters the
myogenic lineage commitment of these cells and induces spontaneous osteogenic and adipogenic
differentiation. This is accompanied by upregulation of key lineage-speciﬁc transcription factors. We
subsequently analyzed genome-wide changes in DNA methylation and polymerase II occupancy during
BMP2-induced osteogenesis. Our data indicate that BMP2 is able to induce the transcriptional program
underlying osteogenesis without changing the methylation status of the genome. We conclude that DNA
methylation primes C2C12 cells for myogenesis and prevents spontaneous osteogenesis, but still permits
induction of the osteogenic transcriptional program upon BMP2 stimulation. Based on these results, we
propose that cell type-speciﬁc DNA methylation patterns are established prior to terminal differentiation of
adult progenitor cells.bone morphogenetic protein;
yltransferase; ESC, embryonic
A immunoprecipitation; MSC,
+31 24 3652999.
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The generation of distinct populations of specialized cells from a
single embryonic stem cell (ESC) is characterized by a progressive
restriction of differentiation potential. ESCs are pluripotent and ﬁrst
differentiate into a variety of multipotent adult stem/progenitor cells
with a differentiation potential that is limited to speciﬁc cell types.
Subsequent lineage commitment gives rise to transit amplifying cells
that undergo a series of cell divisions, thereby stablymaintaining theirlineage characteristics, before terminal differentiation into a special-
ized cell takes place. These processes involve a tightly controlled,
coordinated activation and repression of speciﬁc subsets of genes,
which depend on the orchestrated action of key regulatory transcrip-
tion factors, in combination with changes in epigenetic marks such as
DNA methylation, histone modiﬁcations and chromatin remodeling
[1,2]. These epigenetic marks regulate which regions in the genome
are accessible for transcription and it has been hypothesized that they
thereby contribute to lineage restriction, either by switching off
multipotency-associated genes, or by repressing genes speciﬁc to
other lineages [3].
Methylation of the 5′-position of cytosine in a CpG dinucleotide is a
well-characterized epigenetic modiﬁcation, which is passed on to
daughter cells through so-called maintenance DNAmethyltransferase
(Dnmt) activity upon cell division [4]. This epigenetic mark was
originally considered to mediate stable gene silencing [4], but it has
Table 1
Real-time PCR primer sequences.
Gene Forward primer (5′–3′) Reverse primer (5′–3′)
Acadl GGACTTGCTCTCAACAGCAGTTAC AGGGCCTGTGCAATTGGA
Alpl GACTCGCCAACCCTTCACTG CACCCCGCTATTCCAAACAG
Bglap CCCTGAGTCTGACAAAGCC CTGTGACATCCATACTTGCAG
Dlx5 CAGAACGCGCGGAGTTG CCAGATTTTCACCTGTGTTTGC
Fabp4 GCGTGGAATTCGATGAAATCA GGGCCCCGCCATCTAG
Itga6 TTCCTACCCCGACCTTGCT GGCCGGGATCTGAAAATAGTG
Lpl GCTGGCGTAGCAGGAAGTCT CCAGCTGGATCCAAACCAGTA
Myod1 CGACACAGAACAGGGAACCC GGCCACTCAAGGATCAGCTC
Myog CCAGGAGATCATTTGCTCGC GCACTCATGTCTCTCAAACGG
Pdia2 GAGCATTCAGCCCTGATGGT CTCGGGAGCTAGTTCTTTGCA
Rassf3 GCCGTTACAGACAAGCTGAAGA TGCACCTTAATGAAGCCAGTGT
Rpl19 CCAATGAAATCGCCAATGC CCCATCCTTGATCAGCTTCCT
Sp7 TGCTCCGACCTCCTCAACTT GGCCAGATGGAAGCTGTGA
Tnnc2 CGAGGATGGCAGCGGTACTA CCTTCGCATCCTCTTTCATCTG
Usp15 CCAGATGGGAGATCAAAATGTCT CGTCGCCATCTTTGAGAAGTC
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gene expression strongly depends on its CpG density [5]. DNA
methylation is essential for embryonic development [6,7] and
mediates processes such as X chromosome inactivation [8], genomic
imprinting [9] and silencing of parasitic elements [10].
The involvement of DNA methylation in restriction of develop-
mental potential has been the focus of recent studies in which
high-throughput strategies have been employed to generate and
compare DNA methylation proﬁles of pluripotent ESCs, adult stem/
progenitor cells and/or differentiated somatic cells. First of all,
these studies have shown that pluripotency- and germ line-speciﬁc
genes are hypermethylated in progenitor and differentiated
somatic cells, while these are hypomethylated in ESCs, suggesting
a role for DNA methylation in stable repression of genes required
for maintenance of the unrestricted developmental potential of
ESCs [5,11–13].
In addition, various of these studies, as well as several single-gene
analyses, have identiﬁed regions that are differentially methylated in
distinct cell types and might be associated with lineage-speciﬁc gene
expression, suggesting that DNAmethylationmight also participate in
restriction of the differentiation potential of progenitor cells [13–25].
A role for DNA methylation in lineage restriction is further supported
by the profound effects of treatment with the DNA methylation
inhibitor 5-aza(deoxy)cytidine (5A(d)C) on cellular phenotype
[22,26,27]. For example, it has been shown that treatment of
C3H10T1/2 ﬁbroblasts with 5AC induces differentiation towards
myogenic, adipogenic and chondrogenic lineages, suggesting that
DNA demethylation reverts these cells to a less restricted state, from
which new phenotypes can subsequently differentiate in the absence
of external stimuli [27].
The aforementioned studies have shown that pluripotent ESCs
show lower levels of promoter methylation than specialized somatic
cells. However, it remains unclear at which stages during cellular
development the observed potency- and cell type-related differ-
ences in DNA methylation patterns are formed. Studies on neuronal
differentiation have indicated that methylation contributes to the
conversion of ESCs to adult neuroprogenitors, but not to the
subsequent terminal differentiation [13]. Studies addressing this
issue for cells from other germ layers are, however, still limited [28–
32]. Here, we have addressed late stage development of progenitor
cells of mesodermal origin. To this end, we took advantage of the
robust and homogeneous differentiation characteristics of the
mouse C2C12 myoblast cell line as a model system to study
changes in DNA methylation upon terminal differentiation into
either bone or muscle cells. C2C12 cells were originally derived
from regenerating muscle tissue [33] and are considered to
represent the transit amplifying progenitor population that is
derived from muscle satellite stem cells [34]. When cultured
routinely, C2C12 cells terminally differentiate and fuse into multi-
nucleated myotubes upon reaching conﬂuence, which is preceded
by upregulation of the key myogenic transcription factors Myod1
and Myog. However, treatment of C2C12 cells with bone morpho-
genetic protein (BMP) 2 induces these cells to differentiate into
osteoblasts, which involves the upregulation of key osteogenic
transcription factors Dlx5, Sp7 and Runx2 [35–37], subsequently
leading to the expression of late osteoblast marker genes, such as
Alpl and Bglap [38,39].
We have previously observed differential expression of Dnmts
during BMP2-induced osteogenic differentiation of C2C12 cells,
suggesting remodeling of DNA methylation marks [38]. In the present
study we have used a genome-wide parallel MeDIP (methylated DNA
immunoprecipitation)- and Pol-II (RNA polymerase II) ChIP (chro-
matin IP)-on-chip approach, together with single-gene bisulﬁte
sequencing analyses, to investigate whether lineage-speciﬁc changes
in DNA methylation patterns underlie terminal, multi-lineage differ-
entiation of C2C12 progenitor cells.2. Materials and methods
2.1. Cell culture
Murine C2C12 myoblasts (American Type Culture Collection)
were maintained at sub-conﬂuent densities in Dulbecco's modiﬁed
Eagle's medium (DMEM; Invitrogen, Carlsbad, CA) supplemented
with 10% newborn calf serum (NCS; Thermo Fisher Scientiﬁc,
Waltham, MA), antibiotics (100 U/ml penicillin, 100 μg/ml strepto-
mycin: Sigma-Aldrich, St. Louis, MO), and 2 mM L-glutamine
(Invitrogen), further designated as growth medium (GM), at 37 °C
in a humidiﬁed atmosphere containing 7.5% CO2. To study the effect
of 5AC on differentiation, cells were plated at 1.5×103 cells per cm2
in GM, treated with or without 10 μM 5AC (Sigma-Aldrich) in GM
for 10 days and subsequently maintained on GM. Medium was
replaced every 24 h for the ﬁrst 4 days and every 3–4 days during
the remaining culture period. For growth factor-induced differenti-
ation studies, cells were plated at 2.5×104 cells per cm2 in GM and
grown for 24 h to sub-conﬂuence. Subsequently, medium was
replaced by DMEM containing 5% NCS in the presence or absence
of 300 ng/ml recombinant human bone morphogenetic protein 2
(BMP2; R&D Systems, Minneapolis, MN). Medium was replaced
every 3–4 days.
2.2. Characterization of cellular phenotypes
To study osteogenic differentiation, histochemical analysis of
alkaline phosphatase (Alpl) activity was performed as described
elsewhere [40]. Adipogenic differentiation was characterized by Oil
Red O staining as described previously [41].
2.3. RNA isolation and real-time polymerase chain reaction (PCR)
RNA extraction, reverse transcription and real-time PCR were
performed as described previously [42]. Primer sequences are
presented in Table 1. Gene expression levels are expressed relative
to the housekeeping gene Rpl19.
2.4. Bisulﬁte sequencing
Genomic DNA was isolated using the Wizard® genomic DNA
puriﬁcation kit (Promega, Madison, WI). A total of 700 ng of genomic
DNA was converted with the EZ DNA methylation-gold kit (Zymo
Research, Orange, CA) and ampliﬁed by touchdown PCR with primer
sets designed using MethPrimer software [43]. Primer sequences
are presented in Table 2. PCR mixtures contained 1× PCR buffer, 1×
Q-solution, 1.5 mM MgCl2, 1 unit Taq DNA polymerase (all from
Qiagen, Valencia, CA), 0.4 mM of each dNTP (Fermentas, Burlington,
Table 2
Primer sequences used for bisulﬁte sequencing analysis. Nucleotide positions indicated in bisulﬁte sequencing results were based on the accession numbers included.
Gene Accession number Forward primer (5′–3′) Reverse primer (5′–3′)
Acadl NM_007381 AAGGGGGTTTTTTTAATAATAATAGTTA AAAAACAAATAAATCACTACCAAACC
Actg1 NM_009609 GGTTATTTTTTTTAATTAATTTGGTGT CCCAATAACTTCCTATAACCCTTTC
Ank NM_020332 GTTGTTTTTTGGAAGAGTTGTGTATT ACACCCTTTATTAACCCTTAAAACC
Dlx5 NM_010056 TAATGTTTTGTTGTGTTAAAATTAGTTGGA ACTCTTCTATCAAACACTCCTATCATAAC
Grik3 NM_001081097 TAAGTTATTGGTTTTGTTGAATATAATT CTAACCCCCTCCAAAAATCTAAC
Itga6 NM_008397 AAAGGGGATAATAGTTAAATTTTAGGG AAACTTAACAAAACTAACCAAACTTTTT
Myod1 NM_010866 GGGTATTTATGGGTTTTTTTATAAATTTTTGAGAT CTTCCTCCCAAAATACTAACCTCTCATACCTAATA
Myog NM_031189 GTGTTGTTGAGTAGGAAAGAGAAGG CACCCTACAAACCTACCCCTAAC
Pdia2 NM_001081070 TTTATTGTGGGGAGGAAGGTTATTA AACCTCAAATATCTACATCACACCTATC
Rassf3 NM_138956 TATTAAAGTGAAGAAGTGTTATTTGATT CTATAACCTATTTTCTAACATCACAC
Sp7 NM_130458 TTTTTTAGATTTTTAATTAGTGGTTTGGGGTTTG CAAACCAACTCACTCTTATTCCCACTCAAATC
Tnnc2 NM_009394 GGTGTGAGGTTGATAATTTAATTGG ACCCTAACCAACCTACTTCTTCACT
Usp15 NM_027604 GGTAGGTTTGTATTAAATGGGG AAAAACCAACATAACAAAAAAAATCC
Zc3h13 NM_026083 GGGATGTTTATGATTATAGGGAT TCTCAAATAATTTCTACCATAACTAC
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DNA in a total volume of 50 μl. Cycling parameters were 15 min at
95 °C, followed by 9 touchdown cycles of 30 s at 95 °C, 30 s at 69–
53 °C (2 °C decrease at each cycle) and 40 s at 72 °C, then 32 cycles
of 30 s at 95 °C, 30 s at 53 °C and 40 s at 72 °C, with a subsequent
extension for 10 min at 72 °C. PCR products were isolated from 2%
agarose gels using the QIAquick gel extraction kit (Qiagen) in a ﬁnal
volume of 8 μl, which was subsequently ligated into pCR2.1 using
the TA cloning kit (Invitrogen). Individual clones were sequenced on
a 3730 or 3100 DNA analyzer (Applied Biosystems, Foster City, CA)
using the Big Dye Terminator sequencing kit (Applied Biosystems).
Multiple clones (~10) were sequenced and average methylation
levels are represented in Figs. 2–4 and 6, while data for individual
clones are presented in Supplemental Figs. S1 and S3–S6. All clones
had a C to T conversion at non-CpGs higher than 98%.
2.5. MeDIP- and Pol-II ChIP-on-chip
MeDIP, Pol-II ChIP and subsequent promoter array hybridizations
were performed by Genpathway (San Diego, CA). For MeDIP studies,
genomic DNA from C2C12 cultures was isolated using the ChargeS-
witch gDNA Mini Tissue Kit (Invitrogen) and sonicated to an average
length of 300–500 bp. Genomic DNA from aliquots was puriﬁed for
use as input. For Pol-II ChIP-on-chip, cells were ﬁxed with formalde-
hyde solution (1% formaldehyde, 10 mM NaCl, 100 μM EDTA, 5 mM
HEPES) for 15 min and quenched with 0.125 M glycine for 5 min.
Isolation and sonication of chromatin (to an average length of 300–
500 bp) and immunoprecipitation of methylated and Pol-II bound
DNA fragments were performed as described elsewhere [44]. Brieﬂy,
DNA fragments were immunoprecipitated using antibodies against 5-
methyl-cytosine (P00704; Capralogics, Hardwick, MA) or Pol-II (sc-
9001; Santa Cruz Biotechnology, Santa Cruz, CA) adsorbed to protein-
G-Sepharose beads (Invitrogen). After washing and elution from the
beads with SDS buffer, cross-links in the Pol-II bound chromatin
fragments were reversed by 5 h incubation at 65 °C, which was
followed by successive treatments with RnaseA and proteinase-K.
DNA fragments were ﬁnally puriﬁed by phenol-chloroform extraction
and ethanol precipitation.
Following immunoprecipitation, MeDIP, Pol-II ChIP and input
DNAs were ampliﬁed using the GenomePlex whole-genome ampli-
ﬁcation kit (Sigma-Aldrich) according to the manufacturer's protocol
[45]. Ampliﬁed DNAs were puriﬁed, quantiﬁed and, in parallel with
the original immunoprecipitated DNA, tested by real-time PCR at
speciﬁc genomic regions to assess quality of the ampliﬁcation
reactions. These real-time PCR reactions were performed in triplicate
using SYBR Green Supermix (Bio-Rad, Hercules, CA) and resulting
signals were normalized for primer efﬁciency using input DNA.
Ampliﬁed and input DNAs were subsequently fragmented, labeled
with the DNA Terminal Labeling Kit from Affymetrix and hybridizedovernight at 45 °C to GeneChip Mouse Promoter 1.0R arrays
(Affymetrix, Santa Clara, CA). This array type contains more than 4.6
million 25-mer probes tiled to interrogate over 28,000 murine
promoter regions. Probes are tiled at an average resolution of 35
base pairs, as measured from the central position of adjacent 25-mer
oligonucleotides, spanning from −7.5 kb to +2.5 kb relative to the
transcription start site. Repetitive elements, identiﬁed by RepeatMas-
ker, were not included on the arrays. Promoter regions represented on
the arrays were selected using sequence information from ENSEMBL
genes and RefSeq mRNAs and complete-CDS mRNAs from the NCBI
GenBank.
Arrays were washed and scanned by a GeneChip HT Array Plate
Scanner according to Affymetrix's standard procedures. The result-
ing output CEL ﬁles were analyzed using Affymetrix tiling analysis
(TAS) software to generate, for each time point and treatment,
binary analysis result (BAR) ﬁles containing estimates of fold
enrichment over input DNA (referred to as probe signal values)
for all probes on the array. First, for each array, probe intensities
were normalized using quantile normalization and scaled to set the
median intensity for every array to a target intensity value of 500.
Normalized and scaled intensity values of each probe were then
converted to a linear ‘fold change’ against the intensity of the
corresponding probe on the input DNA array, following which the
‘fold enrichment’ was estimated using the Hodges-Lehmann esti-
mator associated with the Wilcoxon rank-sum test (TAS parameters
for probe analysis; bandwidth=200; sliding window=2× band-
width; test type=one sided upper). TAS software was then used to
identify ‘enriched intervals’, i.e. genomic regions with probe signal
values greater than a threshold of 1.8 for a total length of at least
180 bp (allowing for gaps of maximally 300 bp). Since we were
interested in comparing methylation and Pol-II occupancy between
different samples, and not in absolute values, this threshold was set
less stringent than Affymetrix's recommendation (threshold of 2) to
allow for the identiﬁcation of a larger number of ‘enriched’ sites.
These enriched intervals thus represent the location of signal peaks.
To allow for a direct comparison between enrichment at different
time points and treatments, genomic regions with one or more
enriched intervals in close proximity to each other (at least one base
overlap) were deﬁned as an ‘enriched region’. Enrichment values for
these regions were calculated by averaging the probe signal values
of all probes therein. Exact locations of enriched intervals and
regions along with their proximity to gene annotations were
determined by Chip Analysis Software (Genpathway) based on
NCBI Build 37 (mm9). Enriched regions within 6 kb upstream from a
transcription start site or within a gene were assigned to that
associated gene. The obtained CEL ﬁles and TAS-processed datasets
were deposited into the NCBI GEO database with a series entry of
GSE22077 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
token=lfyntquesowwmdw&acc=GSE22077).
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Graphs of probe signal values and intervals were generated using
the Affymetrix Integrated Genome Browser (IGB). Further represen-
tations of microarray data were visualized using Spotﬁre DXP version
2.2 (Tibco, Palo Alto, CA). Hierarchical clustering of selected enriched
region combinations was performed using UPGMA (unweighted pair-
group method with arithmetic mean) with Euclidean distance as the
similarity measure. Difference in Pol-II occupancy between untreated
and BMP2-treated samples was calculated by averaging the log2 fold
untreated over BMP2-treated Pol-II enrichment values for each time
point, after which the 1000 enriched regions with the largest absolute
value were selected for hierarchical clustering. Muscle- and bone-
related genes were classiﬁed according to gene ontology terms
‘muscle cell differentiation’ (GO: 0042692) and ‘ossiﬁcation’ (GO:
0001503), respectively.
2.7. Statistical analysis
DNA methylation levels of CpGs across the investigated region of
individual clones, obtained by bisulﬁte sequencing, were compared
between different samples using a two-tailed Mann–Whitney U test.
Distributions of muscle- and bone-related enriched regions were
analyzed using the Odds Ratio [46].
3. Results
3.1. 5AC induces C2C12 osteogenic and adipogenic differentiation
To study the effect of DNA hypomethylation on the differentiation
of C2C12 cells, we used 5AC to induce genomic demethylation [47].
C2C12 cells were plated at low densities, treated with 10 μM 5AC for
10 days and subsequently maintained in growth medium for up to
24 days, after which their morphology was monitored. As expected,
untreated cells differentiated into multinucleated myotubes (Fig. 1A).
In contrast, cultures treated with 5AC displayed a variety of different
cellular phenotypes within the same well (Fig. 1B–F). We observed
that approximately 60–70% of the culture dish was covered with
multinucleated cells resembling myotubes, while the remaining cells
were mononucleated and displayed either an elongated, ﬁbroblast-Fig. 1. 5AC induces C2C12 osteogenesis and adipogenesis in the absence of BMP2. C2C12 c
additional 14 days. (A–F): C2C12 cellular morphology after 5AC treatment. Phase-contrast (
cells (F) in day 24 cultures treated with (B–F) or without (A) 5AC. Bar, 50 μm. (G–J): Osteo
without (white bars) 5AC. mRNA levels of osteogenic markers Alpl (G) and Bglap (H) and adip
expressed relative to the housekeeping gene Rpl19.like (Fig. 1B, in between myotubes), a small, cuboid-like (Fig. 1C) or a
round, vacuole-containing morphology (Fig. 1D).
To establish the identity of cells in these mixed populations, we
performed histochemical stainings (Fig. 1E and F) and real-time PCR
analyses for late osteoblast and adipocyte markers (Fig. 1G–J) on day
24 after 5AC treatment. We observed a small number (approximately
1% of the total population) of Alpl-positive foci upon 5AC-treatment,
characteristic for maturating osteoblasts [48]. An example of such an
Alpl-positive group of cells is presented in Fig. 1E. Osteogenic
differentiation was further conﬁrmed by increased mRNA levels of
the late osteoblast markers Alpl (Fig. 1G) and Bglap (Fig. 1H) in the
5AC-treated population. In addition, we observed that approximately
15% of the 5AC-treated cells were positive for Oil Red O (an example of
a positive location is shown in Fig. 1F), characteristic for lipid-
containing adipocytes. This correspondedwith increasedmRNA levels
of the late adipocyte markers Lpl (Fig. 1I) and Fabp4 (Fig. 1J) upon
5AC-treatment.
The ﬁnding that 5AC induces low frequency osteogenesis is in
agreement with previous work demonstrating similar effects upon
treatment with 5AdC [22,49]. Thus, we conclude that treatment with
5AC alters the myogenic lineage commitment of C2C12 cells and
induces low frequency formation of cells with osteogenic and
adipogenic characteristics.
3.2. 5AC induces promoter hypomethylation and mRNA upregulation of
Dlx5 and Sp7
To address DNA methylation changes underlying the 5AC-induced
C2C12 osteogenic differentiation, we next examined the effect of 5AC
on gene expression and promoter methylation of the key osteogenic
transcription factorsDlx5 and Sp7. An increase inDlx5mRNA levelswas
already observed after 2 days in 5AC (Fig. 2A), while upregulation of
Sp7 expression started 3 days after 5AC treatment (Fig. 2B). This time
dependence suggests that the cells undergo at least one round of cell
division before mRNA upregulation takes place, which is consistent
with the mechanism by which 5AC inhibits DNA methylation [47].
We subsequently examined the effect of 5AC treatment on
methylation of the CpG island surrounding the transcription start
site of Dlx5 (Fig. 2C) and the area with the highest CpG density within
1 kb upstream of the Sp7 transcription start site (Fig. 2D) by bisulﬁteells were treated with or without 10 μM 5AC for 10 days and maintained in GM for an
A–D) photomicrographs, and examples of Alpl-positive cells (E) and Oil Red O-positive
genic and adipogenic marker gene expression in cultures treated with (black bars) or
ogenic markers Lpl (I) and Fabp4 (J) were determined in duplicate by real-time PCR and
Fig. 2. 5AC induces demethylation and upregulation of key osteogenic transcription factors. C2C12 cells were treated with (diamonds) or without (circles) 10 μM 5AC for 5 days,
during which RNA was harvested every 24 h for gene expression analysis. DNA was harvested on day 3 for bisulﬁte sequencing. (A–B): mRNA levels of Dlx5 (A) and Sp7 (B) were
determined in duplicate by real-time PCR and expressed relative to the housekeeping gene Rpl19. (C–D): Bisulﬁte sequencing analysis of Dlx5 (C) and Sp7 (D) promoter regions.
Results were averaged for each CpG position, whereby the number of investigated clones is presented between brackets and the shading of each circle represents the percentage of
methylation as indicated. Nucleotide positions of CpGs are indicated relative to the transcription start site. Single-clone data are presented in Supplemental Fig. S3. (E–F): Box plot
representation of bisulﬁte sequence data of Dlx5 (E) and Sp7 (F) promoter regions, in which the percentage of CpG methylation in the investigated region is indicated for each
bacterial clone and median values are indicated by horizontal lines. *pb0.05.
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CpG sites were methylated within the Dlx5 CpG island (Fig. 2C), while
intermediate levels (median of 44%; Fig. 2F) of methylation were
present within the Sp7 promoter (Fig. 2D). In both cases, treatment
with 5AC for 3 days resulted in a signiﬁcant (pb0.05) decrease in DNA
methylation (down to a median of 5% for Dlx5 and of 17% for Sp7;
Fig. 2E and F). These ﬁndings are in agreement with methylation-
speciﬁc PCR data on the effects of 5AdC by Lee et al. [22]. Thus, the
5AC-induced osteogenic conversion of C2C12 cells corresponds toFig. 3. Expression and methylation status of key myogenic and osteogenic transcription fac
(circles) 300 ng/ml BMP2 for 6 days, during which RNA was harvested for gene expression a
mRNA levels ofMyod1 (A), Myog (B), Sp7 (C) and Dlx5 (D) were determined in duplicate by
sequencing analysis ofMyod1 (E) enhancer andMyog (F), Sp7 (G) and Dlx5 (H) promoter reg
clones is presented between brackets and the shading of each circle represents the percentag
to the transcription start site. Single-clone data are presented in Supplemental Fig. S4.promoter hypomethylation and mRNA upregulation of the key
osteogenic transcription factors Dlx5 and Sp7.
3.3. The methylation status of key regulatory genes remains unchanged
during C2C12 myogenesis and BMP2-induced osteogenesis
The ﬁnding that reduction of DNA methylation levels by 5AC
induces C2C12 osteogenic differentiation raises the question whether
the potent osteoinductive factor BMP2 alsomediatesDNAmethylationtors upon C2C12 differentiation. C2C12 cells were treated with (diamonds) or without
nalysis and DNA was harvested for bisulﬁte sequencing at indicated time points. (A–D):
real-time PCR and expressed relative to the housekeeping gene Rpl19. (E–H): Bisulﬁte
ions. Results were averaged for each CpG position, whereby the number of investigated
e of methylation as indicated in Fig. 2. Nucleotide positions of CpGs are indicated relative
844 M. Hupkes et al. / Biochimica et Biophysica Acta 1813 (2011) 839–849changes upon induction of osteogenesis. We therefore studied the
effect of BMP2 on the DNA methylation status of a number of key
differentiation factors, whereby we focused on the regulatory regions
of the genes encoding the myogenic transcription factors Myod1 and
Myog, and the osteogenic transcription factors Dlx5 and Sp7.
Our data presented in Fig. 3A–D show thatMyod1 andMyogmRNA
levels increase upon myogenic differentiation, which is inhibited by
treatment with BMP2, while mRNA levels of Dlx5 and Sp7 are
speciﬁcally upregulated in the presence of BMP2. However, bisulﬁte
sequencing analysis of theMyod1 enhancer [50–52] and Sp7 promoter
revealed no signiﬁcant difference in overall DNA methylation levels
between undifferentiated cells and cells grown for 6 days in the
presence or absence of BMP2 (pN0.05; Fig. 3E and G). Since Dlx5 and
Myog mRNA levels reach a maximum between days 1 and 3 (Fig. 3B
and D), we analyzed the methylation of their promoters 1, 2, 3 and
6 days after induction of differentiation (Fig. 3F and H). For both the
Dlx5 and the Myog promoters, we observed no signiﬁcant differences
in overall DNA methylation levels between any of these time points
and treatments (Fig. 3F and H).
Thus, inhibition of expression of the myogenic transcription factor
genes Myod1 and Myog, as well as induction of the osteogenic
transcription factor genes Dlx5 and Sp7 by BMP2 occurs in the absence
of detectable changes in overall DNA methylation levels of the
regulatory regions examined here.Fig. 4.MeDIP- and Pol-II ChIP-on-chip data of bone- and muscle-related genes. (A): Represe
time points and treatments during C2C12 differentiation. Horizontal lines are plotted at the th
on this threshold value (see Section 2.5) are marked by grey and black bars, respectively.
1000 bp. (B): Scatter plot of MeDIP- versus Pol-II ChIP-on-chip enrichment values in und
0001503; ‘ossiﬁcation’) and grey circles represent muscle-related enriched regions (GO: 0
muscle- (white) related enriched region combinations within; “Total”: the total group of co
valuesN3, and “Pol-IIN3”: the group with Pol-II enrichment valuesN3. *pb10−4. (D): Bisulﬁt
the muscle-related gene Actg1 (bottom). Results were averaged for each CpG position, where
Nucleotide positions of CpGs are indicated relative to the transcription start site. Single-clo3.4. Genome-wide analysis of DNA methylation and Pol-II occupancy
during C2C12 differentiation
To determine whether there are other BMP2-induced changes in
gene expression that, in contrast to Myod1, Myog, Sp7 and Dlx5, do
correspond to a change in DNA methylation, we performed parallel
MeDIP-on-chip and Pol-II ChIP-on-chip studies on undifferentiated
(d0) C2C12 cells and cells treated with (osteogenesis) or without
(myogenesis) BMP2 for 1, 3 and 6 days. This enabled us to directly
compare changes in DNA methylation with changes in transcriptional
activity of a comprehensive set of murine promoter regions during
C2C12 differentiation.
Immunoprecipitated samples were hybridized to Affymetrix
arrays representing over 28,000 promoters in the mouse genome,
after which enrichment values were calculated based on comparison
to an array hybridized with input DNA in order to deﬁne enriched
regions (see Section 2.5). This analysis identiﬁed 18,018 enriched
regions assigned to 13,382 unique genes in the MeDIP dataset, and
26,439 enriched regions assigned to 13,343 genes in the Pol-II dataset.
In total, 8322 genes contained an enriched region in both the MeDIP
dataset (12,225 enriched regions; 68% of total) and the Pol-II dataset
(14,232 enriched regions; 54%). Fig. 4A provides an example of the
Pol-II enriched regions deﬁned for Sp7 and Myog, demonstrating
speciﬁc Pol-II enrichment at these genes in BMP2-treated andntation of Pol-II enrichment at the promoters of Sp7 (left) andMyog (right) at indicated
reshold probe signal value of 1.8, whereby intervals and enriched regions deﬁned based
Positions of the Sp7 and Myog genes are indicated. Bars beneath the genes represent
ifferentiated C2C12 cells. Black circles represent bone-related enriched regions (GO:
042692; ‘muscle cell differentiation’). (C): Relative distribution of bone- (black) and
mbinations related to these GO terms, “MeDIPN3”: the group with MeDIP enrichment
e sequencing analysis of the enriched regions in the bone-related gene Ank (top) and in
by shading of each circle represents the percentage of methylation as indicated in Fig. 2.
ne data are presented in Supplemental Fig. S5.
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those of Sp7 and Myog mRNA expression levels (Fig. 3B and C).
To assess the quality of the MeDIP and Pol-II ChIP-on-chip
procedures, speciﬁc genomic regions were tested in triplicate by
real-time PCR in both the original immunoprecipitated materials and
after ampliﬁcation. For the MeDIP assays Zc3h13, Untr6 (an untran-
scribed region on chromosome 6) and Grik3 were used as hyper-,
hypo-, and intermediately methylated control regions, respectively
(Supplemental Fig. S1). For the Pol-II ChIP assays, Actb, Ppib and Untr6
were used as highly transcriptionally active, intermediately and
inactive control regions, respectively (Supplemental Fig. S2). Differ-
ences in enrichment between these control regions were still
observed, although at a lower magnitude, after ampliﬁcation and
hybridization in both assay types (for negative controls no enriched
regions were detected). The difference in MeDIP values between
Zc3h13 and Grik3 was supported by bisulﬁte sequencing data
(Supplemental Fig. S1D).
To correlate changes in DNA methylation with changes in Pol-II
occupancy during differentiation, we generated a combined dataset in
which all enriched regions assigned to a particular gene in the MeDIP
dataset were compared cross-wise with all enriched regions assigned
to that same gene in the Pol-II ChIP dataset. This resulted in 49,330
enriched region combinations. First concentrating only on the
undifferentiated cells, we present the Pol-II versus the MeDIP
enrichment values for each of these enriched region combinations
in Fig. 4B. Interestingly, high Pol-II and high MeDIP signals appear
mutually exclusive, such that high Pol-II values correspond to low
MeDIP values, while high MeDIP values correspond to low Pol-II
values. These observations are in line with the hypothesis that DNA
methylation mediates gene silencing. We next examined the position
within this scatter plot of enriched regions in genes that have been
assigned to bone- or muscle-related GO terms (Fig. 4B). This subgroup
of bone- and muscle-related enriched regions also displays a “mutual
exclusiveness” between high MeDIP and high Pol-II values. As shown
in Fig. 4C, bone-related enriched regions are signiﬁcantly enriched inFig. 5. Differentiation-speciﬁc changes in Pol-II occupancy correspond to unchanged MeDIP p
the 1000 enriched regions with the largest difference in Pol-II occupancy between untreated
on folds (in log2 scale) of enrichment values at indicated time points and treatments rela
distinguished are indicated. (B,C): Pol-II (left) and MeDIP (right) enrichment of B) osteogen
cluster 2, at indicated time points in untreated (circle) and BMP2-treated (diamond) sampthe group with high (N3) MeDIP values (pb10−4). This observation is
supported by the bisulﬁte sequencing analysis presented in Fig. 4D,
showing that the enriched region in the bone-related Ank gene is
hypermethylated when compared to the enriched region in the
muscle-related Actg1 gene. In addition, muscle-related enriched
regions appear to be more strongly represented in the group with
high (N3) Pol-II values, although at border signiﬁcance (p=0.08).
Together, these observations are in line with the commitment of
untreated C2C12 cells towards the myogenic lineage.
Subsequently, we addressed whether differentiation-induced
changes in gene activity correlate with changes in DNA methylation,
thereby focusing on the 1000 enriched regions (assigned to 250
unique genes; listed in Supplemental Table S1) most differentially
regulated at the level of Pol-II occupancy in untreated versus BMP2-
treated samples (see Section 2.6). We generated a heatmap of this
group of enriched regions based on hierarchical clustering of their
MeDIP and Pol-II folds (on a log2 scale) relative to day 0
(undifferentiated cells) at each time point during the differentiation
process (Fig. 5A). Within this heatmap, two main clusters of enriched
region combinations can be clearly discriminated based on their Pol-II
proﬁles; a ﬁrst one in which Pol-II occupancy increases speciﬁcally
during BMP2 treatment and a second one in which Pol-II occupancy
increases speciﬁcally in untreated cells and remains stable, or even
decreases upon BMP2 treatment. As expected, these two clusters
contain enriched regions assigned to known osteoblast- and myo-
blast-related genes, respectively, including Sp7, Col1a2, Myog and
Myod1 (Fig. 5B and C; left lanes). Interestingly, the second cluster is
much larger (875 enriched regions representing 205 unique genes)
than the ﬁrst one (125 enriched regions; 46 genes), indicating that
more genes are strongly upregulated during myogenic differentiation
than during BMP2-induced osteogenic differentiation of C2C12 cells.
In contrast, the corresponding MeDIP proﬁles showed no such
distinct differentiation-speciﬁc patterns, and fold changes relative to
undifferentiated cells remained low (Fig. 5A). Representative MeDIP
proﬁles corresponding to Sp7, Col1a2, Myog and Myod1, as presentedroﬁles. (A): Heatmap representing hierarchical clustering of MeDIP and Pol-II proﬁles of
and BMP2-treated samples (see Section 2.6). MeDIP and Pol-II intensity values are based
tive to the values at day 0 (undifferentiated cells). The two main clusters that can be
ic genes Sp7 and Col1a2 from cluster 1 and C) myogenic genes Myog and Myod1 from
les.
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signal during both treatments. This is in agreement with our
previously presented bisulﬁte data for the Sp7, Myog and Myod1
regulatory regions (Fig. 3E–G).
While the heatmap presented in Fig. 5A shows overall unchanging
methylation levels for genes that are clearly differentially activated
upon C2C12 differentiation, we next examined whether there might
be individual genes that do have differentiation-speciﬁc Pol-II proﬁles
corresponding to a change in DNA methylation, i.e. whether there are
genes that 1) have a differential Pol-II enrichment pattern during
myogenesis versus osteogenesis and 2) have an anti-correlating
MeDIP pattern. To this end, we calculated the Pearson correlation
coefﬁcient between the MeDIP and Pol-II proﬁles for each combina-
tion of enriched regions in the combined dataset described above. We
then selected the six combinations (assigned to six different genes)
that showed the strongest anti-correlation and the largest difference
between untreated and BMP2-treated samples. In each instance,
however, fold differences between MeDIP values were low (less than
1.7 fold) and bisulﬁte sequencing of these enriched regions did not
reveal a signiﬁcant difference in DNA methylation levels under
conditions where these genes clearly showed differential expression
levels (Fig. 6), again indicating that changes in methylation do not
underlie differentiation-associated changes in gene expression.
Together, these data show that, despite lineage-speciﬁc regulation
of gene expression at the level of Pol-II occupancy, the overall DNA
methylation levels of these genes (including known bone- and
muscle-related genes) remain unchanged in the examined regions
during myogenic and BMP2-induced osteogenic differentiation.
4. Discussion
In the present study we have shown that DNA hypomethylation of
C2C12myoblasts using 5AC results in formation of not onlymyotubes,
but also of osteoblasts and adipocytes. Moreover, 5AC treatment
resulted in activation of key osteogenic transcription factors, in
parallel with demethylation of their promoter regions. In contrast,
upregulation of these same transcription factors during BMP2-
induced osteogenic differentiation was not accompanied by alteration
in their promoter DNA methylation patterns. Genome-wide MeDIP-
and Pol-II ChIP-on-chip analysis also showed no detectable changes in
overall promoter DNA methylation levels of lineage-speciﬁcallyFig. 6. Bisulﬁte sequencing validation of MeDIP proﬁles. Six enriched region combinations
bisulﬁte sequencing. (A–F): Bisulﬁte sequencing analysis of Acadl (A), Rassf3 (B), Itga6 (C
treatments. Results were averaged for each CpG position, whereby the number of investiga
percentage ofmethylation as indicated in Fig. 2. Nucleotide positions of CpGs are indicated re
S6. In some cases, only 5 or less clones were sequenced due to technical difﬁculties. Numb
duplicate by real-time PCR and expressed relative to the housekeeping gene Rpl19.expressed genes. Our data indicate that DNA methylation restricts
spontaneous osteogenic and adipogenic differentiation of C2C12 cells,
but is permissive for the rearrangement of genomic Pol-II occupancy
underlying BMP2-induced osteogenesis.
The mechanism by which 5AC treatment results in spontaneous
differentiation towards the observed mixture of cellular phenotypes
remains unclear. Our observation that 5AC induces signiﬁcant
demethylation and mRNA upregulation of Dlx5 and Sp7, suggests
that activation of these key transcription factors plays a role in the
5AC-induced differentiation. Indeed, it has been shown that over-
expression of each of these master regulators in C2C12 cells can
induce osteogenesis in the absence of additional stimuli [35,53]. The
ﬁnding that only a small percentage of the 5AC-treated cells
differentiate into Alpl-positive osteoblasts might be explained by
the heterogeneity in promoter methylation levels observed following
5AC treatment. It is likely that only in a limited number of cells the
expression levels of Dlx5 and Sp7 are sufﬁciently high to induce
osteogenesis. Alternatively, upregulation of key regulators for other
lineages might suppress osteogenesis in Dlx5 and/or Sp7 positive cells.
While our experiments with 5AC showed that DNA demethylation
can activate expression of key transcription factors, we also
demonstrated that the upregulation of these genes during multi-
lineage differentiation in the absence of 5AC takes place without
signiﬁcant changes in their overall DNA methylation levels. Thus, we
demonstrated at single nucleotide resolution that methylation of the
Myod1, Myog, Dlx5 and Sp7 promoter/enhancer regions studied here
remained unaltered upon both myogenesis and BMP2-induced
osteogenesis, despite lineage-speciﬁc expression patterns. In contrast,
previous studies have demonstrated demethylation of the Myog and
Dlx5 promoter upon C2C12 myogenic and osteogenic differentiation,
respectively [22,23,54,55]. For Dlx5, a BMP2-induced demethylation
of the same promoter region as studied here was demonstrated using
methylation-speciﬁc PCR [22]. The reason for the discrepancy with
our results remains unclear, but may be due to the difference in
methodologies used to study DNA methylation. In the case of Myog,
demethylation of its promoter region after 1–2 days of C2C12
myogenesis, prior to mRNA upregulation, was demonstrated using
both the methylation-sensitive restriction enzyme HpaII [23] and
bisulﬁte sequencing [54,55].While we did observe the lowest levels of
Myog promoter methylation after 2 days of myogenic differentiation
(Fig. 3F), these levels were not signiﬁcantly different from other timewith strongest anti-correlation between MeDIP and Pol-II proﬁles were selected for
), Pdia2 (D), Tnnc2 (E) and Usp15 (F) enriched regions at indicated time points and
ted clones is presented between brackets and the shading of each circle represents the
lative to the transcription start site. Single-clone data are presented in Supplemental Fig.
ers on the right of each ﬁgure represent corresponding mRNA levels as determined in
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result of the conditions used to induce differentiation; while we
culture our cells in 10% NCS and differentiate in 5% NCS, the previously
mentioned studies use 10% and 1% fetal calf serum (FCS) or 2% horse
serum for culture and differentiation, respectively [23,54,55].
Using a parallel MeDIP- and Pol-II ChIP-on-chip approach we
subsequently demonstrated that overall DNA methylation levels of
not only the transcription factors described above, but of basically all
genes whose activity is regulated upon C2C12 differentiation, remain
unaltered in the promoter regions examined here, indicating that
promoter DNA methylation levels in undifferentiated cells are
permissive for both myogenic and osteogenic gene activities. In
light of our previous ﬁndings using 5AC, we therefore propose that the
DNA methylation levels of osteogenic genes in C2C12 cells reﬂect a
subtle balance that prevents spontaneous osteogenesis, but permits
commitment towards this lineage upon growth factor stimulation.
This theory adds to the growing concept of a complex relationship
between DNA methylation and gene expression [5] and suggests that
DNA methylation may contribute to a ﬁne-tuning of gene expression
potential.
In line with this hypothesis, we observed that the DNA
methylation levels of osteoblast-related genes were generally higher
than those of myoblast-related genes, suggesting that DNA methyl-
ation pre-programming could underlie the default differentiation of
C2C12 cells towards themyogenic lineage. This agrees in part with the
recent proposal, put forward by the group of Collas, that promoter
methylation proﬁles may constitute a ‘ground state’ program of gene
activation potential, whereby strong methylation of lineage-speciﬁ-
cation promoters may impose a barrier to differentiation, while
hypomethylation is potentially permissive (i.e. does not seem to have
a predictive value for differentiation potential) [32,56]. This idea was
based on work by the Collas laboratory demonstrating hypermethyla-
tion of the endothelial cell-speciﬁc CD31 promoter in adult human
mesenchymal stem cells (MSCs) derived from adipose tissue (ASCs),
bone marrow (BMMSCs) and muscle (MPCs), which have only
restricted differentiation capacity towards the endothelial lineage,
versus hypomethylation of this locus in adult hematopoietic progen-
itor cells (HPCs), which are capable of endothelial-speciﬁc gene
activation [32,56,57]. Similarly, they observed hypermethylation of
several adipogenic and myogenic promoters in HPCs, representing
lineages for which these cells lack differentiation potential, while
these loci were hypomethylated in MSCs [30,32,56], suggesting that
promoter hypermethylation may predict lineage restriction. On the
other hand, it was also established that most endodermal, mesoder-
mal and ectodermal lineage-speciﬁc promoters are hypomethylated
in both MSCs and HPCs, even though these cell types cannot
differentiate into all of these lineages [32]. Furthermore, ASCs,
BMMSCs andMPCswere all shown to possess similar lowmethylation
levels of myogenic and adipogenic promoters, while MPCs showed
only limited adipogenic differentiation capacity and ASCs and
BMMSCs were unable to undergo myogenesis [56], indicating that
there is no relationship between weak promoter methylation and
differentiation potential. While these studies consider only a
‘hypomethylated’ state (with no predictive value) versus a ‘hyper-
methylated’ state (predicting lineage restriction), our data suggest the
additional existence of ‘intermediate’ methylation states that prevent
gene activity only in the absence of differentiation inducing factors.
Thus, to further investigate whether there is a more subtle
relationship between promoter methylation levels and differentiation
potential, it would be interesting to compare DNA methylation levels
of different sets of lineage-speciﬁc promoters relative to each other
within different types of adult stem/progenitor cells.
We observed that, in general, lineage-speciﬁc transcriptional
activation or repression was not accompanied by a change in DNA
methylation levels of the regions examined in this study. Similarly,
Ezura and colleagues have recently shown that promoter methylationlevels of several key chondrogenic transcription factors, as well as of
several genes that were up- or downregulated upon chondrogenesis,
remained unaltered upon chondrogenic differentiation of human
MSCs [28]. In addition, stable DNA methylation levels were reported
for RUNX2 and BGLAP upon osteogenic differentiation of BMMSCs [29],
for LEP, PPARG2, FABP4 and LPL upon adipogenesis of ASCs [30,56], and
for MYOG upon myogenic differentiation of MPCs [56], despite
transcriptional activation of these genes. Furthermore, genome-wide
studies have shown that terminal differentiation of murine ESC-
derived neuronal progenitors is accompanied by very few changes in
DNA methylation [12,13]. Likewise, a promoter-wide MeDIP-on-chip
study by Sørensen and colleagues demonstrated that, upon both
adipogenic differentiation of human ASCs and myogenesis of human
MPCs, the majority of promoters (see below) retained their
methylation state [32]. These studies indicate that overall DNA
methylation patterns remain stable upon terminal differentiation of
stem/progenitor cells and are, therefore, already largely established
prior to terminal differentiation [20,32]. Our data supports this view
by demonstrating similar ﬁndings for the myogenic and BMP2-
induced osteogenic differentiation of mouse C2C12 myoblasts.
Notably, while the majority (~80%) of promoters in the Sørensen
study described above retained their methylation state upon
differentiation, some methylation changes were described [32].
However, most of these methylation changes were not associated
with a change in transcription. Indeed, only ~0.5% of the promoters
that were originally hypermethylated in progenitor cells underwent a
transcription-related demethylation event. Since our analysis focused
on DNA methylation patterns of promoters that showed differential,
lineage-speciﬁc activation or repression, it remains possible that
methylation changes that are unrelated to these transcriptional
events do occur in our system, though the signiﬁcance thereof on
the establishment of lineage-speciﬁc transcriptional programs would
be unclear. The identiﬁcation by Sørensen et al. of a small group of
promoters for which demethylation upon MPC and ASC differentia-
tion was associated with an upregulation of gene expression, while
we did not observe such events, might be explained by the difference
in progenitor cell types used. Murine C2C12 myoblasts are already
committed to the myogenic lineage and therefore represent a slightly
further restricted progenitor type than humanMSCs. This ﬁnding that
DNA methylation patterns appear to be even more stable in more
restricted progenitor cells ﬁts well within the above proposal that
DNA methylation patterns are largely established prior to terminal
differentiation.
While our study has shown that, in general, C2C12 lineage-speciﬁc
transcriptional programs are not associated with changes in overall
DNA methylation patterns of the corresponding gene promoters, we
must note a few limitations of our approach. First, our study has
focused on the DNA methylation levels of (genome-wide) promoter
regions. Therefore, we cannot rule out the possibility that DNA
methylation changes do occur outside of promoter areas, as was
shown by others [12,14,15,17,20,58–60]. Second, the MeDIP-on-chip
technique monitors overall promoter methylation levels and does not
detect changes at single CpG sites.
As a ﬁnal point, in light of previous studies that have demonstrated
distinct differences in methylation proﬁles between pluripotent ESCs
and multipotent adult stem cells and/or differentiated somatic cells
[5,11–13], the ﬁnding that promoter DNA methylation patterns
remain overall stable upon terminal differentiation of adult stem/
progenitor cells indicates that DNA methylation changes mainly
characterize the differentiation of pluripotent ESCs towards a more
restricted, multipotent state and are less involved in late-stage
development. Terminal differentiation, however, does involve unidi-
rectional progression through a tightly controlled gene expression
program that is transmitted to daughter cells upon cell division. It is
therefore likely that other epigenetic mechanisms, such as histone
modiﬁcations or expression of microRNAs, play a more prominent
848 M. Hupkes et al. / Biochimica et Biophysica Acta 1813 (2011) 839–849role in late-stage differentiation. Indeed, a role for a number of
microRNAs, as well as several different histone modiﬁcations, in
particular H3 and H4 lysine (de)acetylation and H3 lysine methyla-
tion, has been established in the regulation of gene expression during
myogenic and osteogenic differentiation [61–66]. We are currently
further investigating the role of such modiﬁcations in multi-lineage
terminal differentiation of C2C12 cells.
5. Conclusions
While genomic demethylation has pronounced effects on lineage
commitment of C2C12 myoblasts, DNA methylation does not appear
to play a large role in establishing the cell type-speciﬁc transcriptional
programs induced upon myogenic and BMP2-induced osteogenic
differentiation. Our results do indicate that DNA methylation primes
C2C12 cells for myogenesis, while preventing osteogenesis in the
absence of the osteoinductive factor BMP2. We propose that lineage-
speciﬁc DNA methylation patterns are established prior to terminal
differentiation of adult multipotent stem/progenitor cells.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbamcr.2011.01.022.
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